74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Veracyte Inc
Closed
Sector Healthcare
39.24 -4.34
Overview
Share price change
24h
Min
38.54
Max
39.49
Income | 9.4M 15M |
|---|---|
Sales | 1.5M 116M |
EPS | 0.19 |
Profit margin | 13.08 |
Employees | 815 |
EBITDA | 9.6M 23M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +30.17 upside |
Next Earnings | 24 Feb 2025 |
|---|
Market Cap | -304M 3.3B |
|---|---|
Previous open | 43.58 |
Previous close | 39.24 |
News Sentiment
By Acuity
17%
83%
19 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Veracyte Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Veracyte Inc Forecast
Price Target
By TipRanks
30.17% upside
12 Months Forecast
Average 51 USD 30.17%
High 51 USD
Low 51 USD
Based on 2 Wall Street analysts offering 12 month price targets forVeracyte Inc - Dist in the last 3 months.
Sentiment
By Acuity
19 / 393 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
